Ensysce Biosciences Inc Ordinary Shares ENSC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
-
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
-
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
-
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
-
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
-
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
-
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
-
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.39–0.44
- 52-Week Range
- $0.23–2.75
- Bid/Ask
- $0.40 / $0.43
- Shares Outstanding
- 19.46M
- Market Cap
- $8.15M
- Volume/Avg
- 603,271 / 14M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.ensysce.com
Valuation
|
Metric
|
ENSC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ENSC
|
|---|---|
Quick Ratio | 0.27 |
Current Ratio | 0.70 |
Interest Coverage | −788.32 |
Quick Ratio
ENSC
Profitability
|
Metric
|
ENSC
|
|---|---|
Return on Assets (Normalized) | −296.29% |
Return on Equity (Normalized) | −945.54% |
Return on Invested Capital (Normalized) | −956.18% |
Return on Assets
ENSC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<g?L$^ | LOCK|@RzLm | $128B | |||
| Moderna Inc
MRNA
| LOCK|<!>xMg | LOCK|&s@ | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g>B^fK | LOCK|<VXCs | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Hr$?v?& | LOCK|H! | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%J!p^#? | LOCK|^^g | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>$@FM# | LOCK|H>&w | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>scz#z&c | LOCK|J!r> | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G&>z@^ | LOCK|!z> | $25B | |||
| Incyte Corp
INCY
| LOCK|X!#N@gM | LOCK|kv | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Q$Nxwq | LOCK|s? | $15B |
United States